Femasys Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FEMY research report →
Price Chart
About the company
Femasys Inc. , a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering.
- CEO
- Kathy Lee-Sepsick
- IPO
- 2021
- Employees
- 53
- HQ
- Suwanee, GA, US
Get TickerSpark's AI analysis on FEMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.73M
- P/E
- -0.32
- Fwd P/E
- 0.36
- PEG
- -0.00
- P/S
- 5.44
- P/B
- 0.15
- EV/EBITDA
- 0.80
- Div Yield
- 0.00%
- Gross Margin
- 50.81%
- Op Margin
- -929.87%
- Net Margin
- -640.89%
- ROE
- -114.48%
- ROIC
- -61.06%
Latest fiscal year · YoY change
- Revenue
- $2.29M+40.8%
- Gross Profit
- $1.42M+31.1%
- Op Income
- $-17,588,669
- Net Income
- $-18,627,887+1.0%
- EPS
- $-9.40+44.0%
- OCF Growth
- +3.9%
- FCF Growth
- +4.9%
- 52W High
- $20.80
- 52W Low
- $1.07
- 50D MA
- $1.83
- 200D MA
- $5.39
- Beta
- -2.17
- RSI (14)
- 38
- Avg Volume
- 118.39K
No earnings-call transcripts are available for FEMY yet.
- Free Float
- 79.5%
- Shares Outstanding
- 8.66M
- Float Shares
- 6.88M
of shares held by institutions
2 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.42M | ▲ 463.69K |
| Pandora Wealth, Inc. | 15.00K | 0 |
| Cx Institutional | 750 | 0 |
Held by 21 ETFs
Biggest fund positions in FEMY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Moorhead John Hunnewell Jr | other | 1,760 |
| Oct 30, 26 | Moorhead John Hunnewell Jr | other | 0 |
| Jun 24, 26 | Eichenbaum Kenneth D. | other | 880 |
| Jun 24, 26 | Uzialko Edward R | other | 880 |
| Jun 24, 26 | Milnes Alistair | other | 880 |
| Jun 24, 26 | Larsen Charles | other | 880 |
| Aug 7, 26 | Mifek Jeffrey Gerald | buy | 3,125 |
| Aug 7, 26 | Mifek Jeffrey Gerald | other | 3,125 |
| Aug 7, 26 | Mifek Jeffrey Gerald | other | 3,125 |
| Jul 6, 26 | Mifek Jeffrey Gerald | other | 6,250 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FEMY coverage
Recent articles, reports, and earnings notes.
No research on FEMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FEMY report →Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
globenewswire.com · Nov 13
Femasys Appoints John Moorhead to Board of Directors
globenewswire.com · Oct 30
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
globenewswire.com · Oct 20
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
globenewswire.com · Oct 14
Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.
seekingalpha.com · Oct 14
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
globenewswire.com · Oct 8
Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)
defenseworld.net · Sep 30
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care
globenewswire.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.